Long-term Safety of Coded Unani Formulation and PUVASOL in Patients with Vitiligo - A Randomized Comparative Controlled Clinical Trial

Authors:

Abstract
Background: Vitiligo, a skin disorder is viewed as a multifactorial process characterized by the acquired loss of constitutional pigmentation manifesting as white macules and patches. The Unani system of medicine offers many formulations including the ones designed by the Central Council for Research in Unani Medicine for the successful treatment of vitiligo. Aims and Objectives: Herein, we evaluated the comparative long-term safety (9 months) of test Unani formulation (UNIM 001 and UNIM 003) with controlled allopathic therapy (PUVASOL: Psoralen and UVA obtained by solar light) in terms of blood parameters. Materials and Methods: In this clinical study, 39 vitiligo patients in the test group and 33 vitiligo patients in the control group were assessed for blood parameters viz., aspartate aminotransferase, alanine aminotransferase, bilirubin, urea, creatinine, hemoglobin, red blood cells, white blood cell, and Platelet before, during, and after the treatment period. Results: All the blood parameters were in the normal biological reference range in the test and control group at the baseline, during the treatment, and at the end of the study. These results indicate that at a given dose of the UNIM-001 and UNIM 004, there is no effect on the liver, kidney, and other hematological blood parameters in the patients with vitiligo and are comparable with PUVASOL therapy. Conclusion: A combination of Unani formulation i.e., UNIM 001 as oral and UNIM 003 as topical application may be considered an effective and safe treatment alternative to patients with vitiligo.

This publication has 6 references indexed in Scilit: